Onco Wiki / Red flag

Frailty profile precluding standard FL combination immunochemo (BR / R-CHOP / G-B / R-Len...

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Red Flag Origin

Trigger Logic

{
  "any_of": [
    {
      "comparator": ">=",
      "finding": "ecog",
      "threshold": 3
    },
    {
      "all_of": [
        {
          "comparator": ">=",
          "finding": "age",
          "threshold": 80
        },
        {
          "comparator": ">=",
          "finding": "comorbidity_grade2_count",
          "threshold": 1
        }
      ]
    },
    {
      "all_of": [
        {
          "comparator": ">=",
          "finding": "age",
          "threshold": 75
        },
        {
          "comparator": ">=",
          "finding": "charlson_score",
          "threshold": 3
        },
        {
          "comparator": "<",
          "finding": "albumin_g_dl",
          "threshold": 3.5
        }
      ]
    }
  ],
  "type": "composite_score"
}

Notes

FL is indolent and frequently watch-and-wait appropriate. When treatment is required (per GELF criteria), rituximab monotherapy weekly x4 then maintenance — well-tolerated, response durable in low-burden disease, and can be repeated at progression. Rituximab + chlorambucil oral schedule (StiL NHL2) reasonable for mid-frailty. Avoid bendamustine in elderly with active infection / prior PJP / hypogamma — opportunistic infection risk substantial. Lenalidomide in frail elderly causes cytopenias / fatigue — start reduced-dose (10 mg) and titrate.

Used By

No reverse references found in the YAML corpus.